Ilsung Is Co., Ltd. (KRX:003120)

South Korea · Delayed Price · Currency is KRW

19,200

+210 (1.11%)

Jun 24, 2026, 3:30 PM KST

-17.24% (1Y)

Market Cap	133.80B +1.1%
Revenue (ttm)	64.38B -7.6%
Net Income	1.20B -92.1%
EPS	173.16 -92.3%
Shares Out	6.97M
PE Ratio	110.88
Forward PE	n/a
Dividend	1,200.00 (6.25%)
Ex-Dividend Date	Dec 29, 2025

Volume	11,592
Open	18,910
Previous Close	18,990
Day's Range	18,560 - 19,200
52-Week Range	18,100 - 31,450
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Ilsung Is

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular sys... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1954

Country South Korea

Stock Exchange Korea Stock Exchange

Ticker Symbol 003120

Full Company Profile

Financial Performance

In 2025, Ilsung Is's revenue was 64.29 billion, a decrease of -6.85% compared to the previous year's 69.02 billion. Earnings were 1.17 billion, a decrease of -91.10%.

Financial Statements